SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca announced positive high-level results from two Phase III…

ASTRAZENECA PLC · 6-K filed Mar 27, 2026 at 08:04 ET

At the news

BULLISHIMPACT 8/10

6-K filed Mar 27, 2026 at 08:04 ET

AstraZeneca announced positive high-level results from two Phase III trials (OBERON and TITANIA) showing that tozorakimab, an IL-33-targeting biologic, significantly reduced moderate-to-severe COPD exacerbations in a broad patient population. This marks the first time an IL-33 inhibitor has demonstrated such efficacy in replicate Phase III trials, representing a major scientific advancement in COPD treatment.

  • Tozorakimab met primary endpoints in both OBERON and TITANIA Phase III trials, reducing annualized rates of moderate-to-severe COPD exacerbations versus placebo.
  • The drug showed efficacy in former smokers (primary population), current smokers, across all blood eosinophil counts, and all stages of lung function severity.
  • Tozorakimab was generally well tolerated with a favorable safety profile.
  • It is a first-in-class monoclonal antibody targeting both reduced and oxidized forms of IL-33, uniquely inhibiting inflammation and mucus dysfunction in COPD.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access